Anebulo Pharmaceuticals, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Stock-Based Compensation (Tables)

Stock-Based Compensation (Tables)

9 Months Ended

Mar. 31, 2023

Share-Based Payment Arrangement [Abstract]

Schedule of Fair Value Assumptions of Stock Options

The following table summarizes the range of key assumptions used to determine the fair value of stock options granted during the three and nine months ended March 31, 2023 and 2022.

	Three Months Ended March 31,						Nine Months Ended March 31,
	2023			2022			2023			2022
Risk-free interest rate		–	%		1.29% – 2.14	%		2.87% – 4.32	%		0.79% – 2.14	%
Expected term (in years)		–			4.5			4.5 – 6.25			3.0 – 4.5
Expected volatility		–	%		50.0	%		50.0 – 60.0	%		50	%
Expected dividend yield		–			–			–			–

Schedule of Stock Option Activity

The following table summarizes stock option activity for the nine months ended March 31, 2023:

Schedule of Stock Option Activity

	Number of Shares			Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (Years)		Aggregate Intrinsic Value

Outstanding at June 30, 2022		1,911,459		$	4.63		4.4		-
Granted		172,654		$	3.31
Exercised		(24,000	)	$	2.18
Forfeited		(10,800	)	$	6.00
Outstanding at March 31, 2023		2,049,313		$	4.54		4.0	$	415,956
Options exercisable at March 31, 2023		661,867		$	4.33		3.4		250,815

Schedule of Stock-Based compensation Expenses

The Company recorded stock-based compensation expenses for the following periods:


	Three Months Ended				Nine Months Ended
	March 31,				March 31,
	2023		2022		2023		2022
Research and development	$	-	$	245	$	-	$	12,233
General and administrative		223,637		125,009		661,158		241,476
Total stock-based compensation expense	$	223,637	$	125,254	$	661,158	$	253,709